Date: 2016-03-24
Type of information: Collaboration agreement
Compound: targeted radio conjugates
Company: ITM Isotopen Technologien München AG (ITM) (Germany) Scil Proteins (Germany)
Therapeutic area:
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On March 24, 2016, ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, and Scil Proteins, a company specialized in affinity ligands and targeted carriers, announced they have entered into a partnership covering the field of targeted radio conjugates. Under the terms of the agreement the partners plan to cover a number of programs for the discovery and development of novel targeted radio conjugates for imaging and therapy purposes, in a variety of indications. Scil Proteins will be responsible for the discovery and design of the radio conjugates based on its proprietary Affilin® platform, while ITM will use its radioisotope technology and be responsible for later-stage development and commercialization of the resulting products. The first program has commenced in the area of targeted cancer treatment. Affilin®-based biomolecules are derived from human scaffold proteins and have high stability, affinity and specificity making them ideal for a range of applications, including those where antibodies have limitations, thus broadening the potential of biotherapeutics.
Financial terms:
Latest news:
